| Anas Younes, M.D. |
Present Title & Affiliation
Primary Appointment
Director, Clinical and Translational Research Program, Department of Lymphoma/Myeloma, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston
Education & Training
Degree-Granting Education | |
| 1983 | The University of Damascus School of Medicine, Damascus, Syria, MD, Medicine |
Postgraduate Training | |
| 7/1989-6/1992 | Fellow, Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 7/1986-6/1989 | Residency in Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY |
| 7/1985-6/1986 | Residency in Pathology, Medical College of Ohio, Toledo, OH |
| 7/1984-6/1985 | Guest Researcher, Endocrine and Reproductive Research Branch (ERRB), NICHD, National Institutes of Health, Bethesda, MD, Dr. Kevin Catt |
Board Certifications
| 11/1991 | American Board of Medical Oncology |
| 9/1989 | American Board of Internal Medicine |
Experience/Service
Academic Appointments
Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, U.T. M.D. Anderson Cancer Center, Houston, TX, 2003-present
Administrative Appointments/Responsibilities
Team Leader, Hodgkin Lymphoma Program, Department of Lymphoma/Myeloma, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX, 2004-present
Team Leader, Lymphoma and Myeloma Drug Development Program, Department of Lymphoma/Myeloma, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX, 2003-present
Institutional Committee Activities
Member, Institution Review Board (IRB), 1/1992-1/1994
Honors and Awards
| 2009 | EAB member , Metabolism Branch, NCI |
| 1996-1999 | Clinical Oncology Career Development Award, American Cancer Society |
| 1996-1999 | Faculty Excellence Award, M.D. Anderson Cancer Center |
| 1991-1992 | Clinical Scholars Award for Biomedical Research, Sloan-Kettering Institute |
| 1991-1992 | Dana Research Fellow, Sloan-Kettering Institute |
Professional Memberships
| American Society of Clinical Oncology, Orlando, FL Member, 1/1992-present |
| International Congress on Hodgkin Lymphoma, Cologne, Germany Member/Scientific Advisory Board, 1/2007-present |
| Lymphoma Research Foundation, Dallas, TX Member, 3/2008-present |
| Southwest Oncology Group, Chicago, IL Member, 1/2006-present |
| University of Iowa/Mayo Lymphoma SPORE, Iowa City, IA Member, EAB, 1/2007-present |
Selected Publications
Peer-Reviewed Original Research Articles | ||
| 1. | Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios V. Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, III, Sang Hoon Lee, Sharon Lea Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William Wierda, Susan O'Brien, and Anas Younes. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 112:711-20, 8/2008. | |
| 2. | Daniela Buglio, Georgios V. Georgakis, Shino Hanabuchi, Kazuhiko Arima, Noor M. Khaskhely, Yong-Jun Liu, and Anas Younes. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112(4):1424 - 1433, 8/2008. e-Pub 6/2008. PMCID: PMC2515130. | |
| 3. | Bertrand Coiffier, Arnold Altman, Ching-Hon Pui, Anas Younes, and Mitchell S. Cairo. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. J Clin Oncol 26(16):2767-78, 6/2008. PMID: 18509186. | |
| 4. | M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, F. Cabanillas, M. A. Rodriguez, and L. E. Fayad. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553 - 559, 3/2008. e-Pub 12/2007. PMID: 18083690. | |
| 5. | Paolo Anderlini, Rima Saliba, Sandra Acholonu, Sergio A. Giralt, Borje Andersson, Naoto T. Ueno, Chitra Hosing, Issa F. Khouri, Daniel Couriel, Marcos de Lima, Muzaffar H. Qazilbash, Barbara Pro, Jorge Romaguera, Luis Fayad, Frederick Hagemeister, Anas Younes, Mark F. Munsell, and Richard E. Champlin. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 2/2008. | |
| 6. | Kwang Seok Ahn, Gautam Sethi, Ta-Hsiang Chao, Saskia T. C. Neuteboom, Madan M. Chaturvedi, Michael A. Palladino, Anas Younes, and Bharat B. Aggarwal. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-B–regulated gene products. Blood 110:2286-95, 10/2007. | |
| 7. | JP Leonard, JW Friedberg, A Younes, D Fisher, LI Gordon, J Moore, M Czuczman, T Miller, P Stiff, BD Cheson, A Forero-Torres, N Chieffo, B McKinney, D Finucane, and A Molina. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 18(7):1216-23, 7/2007. e-Pub 4/2007. PMID: 17470451. | |
| 8. | Yasuhiro Oki and Anas Younes. Endothelial progenitor cells in non-Hodgkin’s lymphoma. Haematologica 92:433-4, 4/2007. | |
| 9. | Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109(5):2174-82, 3/2007. e-Pub 11/2006. PMCID: PMC1801039. | |
| 10. | Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 34(12):1670-9, 12/2006. PMID: 17157164. | |
| 11. | Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 11/2006. e-Pub 9/27/2006. PMID: 17008093. | |
| 12. | Wedgwood A, Younes A. Targeting lymphoma cells and their microenvironment with novel antibodies. Clin Lymphoma Myeloma 7 Suppl 1:S33-40, 10/2006. PMID: 17101071. | |
| 13. | Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 135(1):68-71, 10/2006. e-Pub 8/22/2006. PMID: 16925576. | |
| 14. | Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(9):1818-21, 9/2006. PMID: 17064994. | |
| 15. | Yazbeck V, Georgakis GV, Wedgwood A, Younes A. Hodgkin's lymphoma: molecular targets and novel treatment strategies. Future Oncol 2(4):533-51, 8/2006. PMID: 16922620. | |
| 16. | Qi Liu, Luis Fayad, Fernando Cabanillas, Fredrick B. Hagemeister, Gregory D. Ayers, Mark Hess, Jorge Romaguera, M. Alma Rodriguez, Apostolia M. Tsimberidou, Srdan Verstovsek, Anas Younes, Barbara Pro, Ming-Sheng Lee, Ana Ayala, and Peter McLaughlin. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582 - 1589, 4/2006. PMID: 16575009. | |
| 17. | Georgakis, G. V., Li, Y., Rassidakis, G. Z., Martinez-Valdez, H., Medeiros, L. J., and Younes, A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 12(2):584-590, 1/2006. PMID: 16428504. | |
| 18. | Valbuena JR, Rassidakis GZ, Lin P, Atwell C, Georgakis GV, Younes A, Jones D, Medeiros LJ. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol 18(10):1343-9, 10/2005. PMID: 16056252. | |
| 19. | Jorge E. Romaguera, Luis Fayad, Maria A. Rodriguez, Kristine R. Broglio, Frederick B. Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Andreas H. Sarris, Nam H. Dang, Michael Wang, Virginia Beasley, L. Jeffrey Medeiros, Ruth L. Katz, Harish Gagneja, Barry I. Samuels, Terry L. Smith, and Fernando F. Cabanillas. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. J Clin Oncol 23(28):7013 - 23, 10/2005. e-Pub 9/2005. PMID: 16145068. | |
| 20. | Ha CS, Cabanillas F, Lee MS, Tucker SL, McLaughlin P, Rodriguez MA, Younes A, Romaguera JE, Mesina OM, Cox JD. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. Int J Radiat Oncol Biol Phys 63(1):188-93, 9/2005. PMID: 16111588. | |
| 21. | Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-7, 8/2005. PMID: 15973667. | |
| 22. | Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345-53, 7/2005. PMID: 15948158. | |
| 23. | Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23(19):4390-8, 7/2005. PMID: 15994148. | |
| 24. | Wedgwood A, Pro B, Younes A. The lymphomas: molecular pathways and novel therapeutic targets. Curr Hematol Rep 4(4):324-34, 7/2005. PMID: 16009048. | |
| 25. | Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 5/2005. PMID: 15806128. | |
| 26. | Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 1(2):273-81, 4/2005. PMID: 16555999. | |
| 27. | Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23(4):712-9, 2/2005. e-Pub 12/2004. PMID: 15613695. | |
| 28. | Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2/2005. e-Pub 12/2004. PMID: 15613697. | |
| 29. | Younes A. New treatment strategies for aggressive lymphoma. Semin Oncol 31(6 Suppl 15):10-3, 12/2004. PMID: 15726533. | |
| 30. | Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3(10):1249-62, 10/2004. PMID: 15486192. | |
| 31. | Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 10/2004. e-Pub 9/2004. PMID: 15353540. | |
| 32. | Pro B, Younes A. New molecular targets for treatment of lymphoma. Curr Oncol Rep 6(5):360-8, 9/2004. PMID: 15291979. | |
| 33. | Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines 3(4):403-11, 8/2004. PMID: 15270645. | |
| 34. | Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 17(8):946-53, 8/2004. PMID: 15105813. | |
| 35. | Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10(16):5432-8, 8/2004. PMID: 15328181. | |
| 36. | Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10(9):3207-15, 5/2004. PMID: 15131062. | |
| 37. | Zheng B, Geogakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 kappaB mutations or activation of CD30, CD40, and RANK receptors 10(9):3207-15, 5/2004. | |
| 38. | Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100(6):1186-9, 3/2004. PMID: 15022285. | |
| 39. | Rassidakis GZ, Georgakis GV, Younes A, Medeiros LJ. c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Blood 102(13):4619-20, 12/2003. PMID: 14656871. | |
| 40. | Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-12, 12/2003. PMID: 14645431. | |
| 41. | Younes A, Carbone A. Clinicopathologic and molecular features of Hodgkin's lymphoma. Cancer Biol Ther 2(5):500-7, Sep-Oct, 9/2003. PMID: 14614314. | |
| 42. | Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21(18):3526-34, 9/2003. PMID: 12972530. | |
| 43. | Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, Sep-Oct, 9/2003. PMID: 12883733. | |
| 44. | Yorke R, Younes A, Chirala M, Younes M. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. Eur J Cancer 39(14):2099-102, 9/2003. PMID: 12957466. | |
| 45. | Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 98(3):458-67, 8/2003. PMID: 12879461. | |
| 46. | Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102(3):1019-27, 8/2003. PMID: 12689928. | |
| 47. | Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98(2):310-4, 7/2003. PMID: 12872350. | |
| 48. | Younes A, Garg A, Aggarwal BB. Nuclear transcription factor-kappaB in Hodgkin's disease. Leuk Lymphoma 44(6):929-35, 6/2003. PMID: 12854890. | |
| 49. | Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2/2003. PMID: 12548600. | |
| 50. | Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100(13):4351-7, 12/2002. e-Pub 8/8/2002. PMID: 12393618. | |
| 51. | Fanale MA, Younes A. Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Drugs 67(3):333-50, 2002. PMID: 17335294. | |
| 52. | Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 8(5):377-83, Sep-Oct, 9/2002. PMID: 12416895. | |
| 53. | Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94(6):1731-8, 3/2002. PMID: 11920535. | |
| 54. | Mukhopadhyay A, Fiumara A., Li Y, Darnay BG, Aggarwal B, Younes A. Receptor Activator of Nuclear Factor-kB (RANK) Ligand Activates Mitogen-Activated Protein Kinases Signaling Pathways in Hodgkin/Reed-Sternberg Cells. Blood 2002:3485-3486, 1/2002. | |
| 55. | Clodi K, Asgari Z, Younes M, Palmer JL, Cabanillas F, Carbone A, Andreeff M, Younes A. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 94(1):1-5, 2002. PMID: 11815953. | |
| 56. | Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98(13):3595-9, 12/2001. PMID: 11739162. | |
| 57. | Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB, Younes A. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98(9):2784-90, 11/2001. PMID: 11675352. | |
| 58. | Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol 32(9):940-4, 9/2001. PMID: 11567223. | |
| 59. | Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19(17):3766-70, 9/2001. PMID: 11533100. | |
| 60. | King KM, Younes A. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 1(2):177-86, 8/2001. PMID: 12113023. | |
| 61. | Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park) 15(7 Suppl 8):53-6, 7/2001. PMID: 11497233. | |
| 62. | Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 12(7):923-7, 7/2001. PMID: 11521796. | |
| 63. | Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 20(29):3757-65, 6/2001. PMID: 11439339. | |
| 64. | Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 113(2):265-74, 5/2001. PMID: 11380390. | |
| 65. | Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A, Brenner MK. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 8(5):378-87, 5/2001. PMID: 11477458. | |
| 66. | van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 27(4):397-404, 2/2001. PMID: 11313669. | |
| 67. | 1. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal B.B, Younes A. Functional Expression of RANK in Hodgkin disease cell lines. Blood 98:2784-2790, 1/2001. | |
| 68. | Fiumara P, Cabanillas F, Younes A. IL-13 in sera of patients with Hodgkin disease. Blood 98:2877-2878, 1/2001. | |
| 69. | Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk Lymphoma 40(1-2):79-85, 12/2000. PMID: 11426631. | |
| 70. | McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37-41, 12/2000. PMID: 11225999. | |
| 71. | Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, Gadner H, Younes A. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111(2):580-6, 11/2000. PMID: 11122106. | |
| 72. | Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 39(3-4):291-9, 10/2000. PMID: 11342309. | |
| 73. | Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39(1-2):77-85, 9/2000. PMID: 10975386. | |
| 74. | Younes M, Lechago J, Ertan A, Finnie D, Younes A. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Hum Pathol 31(4):434-8, 4/2000. PMID: 10821489. | |
| 75. | Younes M, Schwartz MR, Ertan A, Finnie D, Younes A. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 88(3):524-8, 2/2000. PMID: 10649242. | |
| 76. | King K, Younes A. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma. Semin Oncol 27(1 Suppl 1):14-22, 2/2000. PMID: 10697039. | |
| 77. | Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11 Suppl 1:137-40, 2000. PMID: 10707796. | |
| 78. | Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11 Suppl 1:137-40, 2000. PMID: 10707796. | |
| 79. | Younes M, Schwartz MR, Finnie D, Younes A. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol 30(11):1309-13, 11/1999. PMID: 10571510. | |
| 80. | Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 35(3-4):317-24, 10/1999. PMID: 10706456. | |
| 81. | Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol 106(3):827-32, 9/1999. PMID: 10468881. | |
| 82. | Younes A. The dynamics of life and death of malignant lymphocytes. Curr Opin Oncol 11(5):364-9, 9/1999. PMID: 10505772. | |
| 83. | Ayoub JP, Palmer JL, Huh Y, Cabanillas F, Younes A. Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk Lymphoma 34(5-6):519-27, 8/1999. PMID: 10492075. | |
| 84. | Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131(2):88-95, 7/1999. PMID: 10419446. | |
| 85. | Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 14(3):135-43, 7/1999. PMID: 10569134. | |
| 86. | Lopez-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93(9):3081-7, 5/1999. PMID: 10216105. | |
| 87. | Younes A. Paclitaxel-based treatment of lymphoma. Semin Oncol 26(1 Suppl 2):123-8, 2/1999. PMID: 10190794. | |
| 88. | Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs 17(2):187-92, 1999. PMID: 10638491. | |
| 89. | Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16(12):3803-9, 12/1998. PMID: 9850025. | |
| 90. | Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 32(1-2):97-106, 12/1998. PMID: 10037005. | |
| 91. | Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol 103(3):678-83, 12/1998. PMID: 9858216. | |
| 92. | Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 103(1):270-5, 10/1998. PMID: 9792321. | |
| 93. | Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 103(1):217-9, 10/1998. PMID: 9792311. | |
| 94. | Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91(8):2955-60, 4/1998. PMID: 9531606. | |
| 95. | van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178-84, 2/1998. PMID: 9454747. | |
| 96. | Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 100(1):135-41, 1998. PMID: 9450802. | |
| 97. | Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99(3):618-24, 12/1997. PMID: 9401075. | |
| 98. | Younes A, Consoli U, Snell V, Clodi K, Kliche KO, Palmer JL, Gruss HJ, Armitage R, Thomas EK, Cabanillas F, Andreeff M. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 15(11):3355-62, 11/1997. PMID: 9363866. | |
| 99. | Munker R, Younes A, Cabanillas F, Andreeff M. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk Lymphoma 27(5-6):517-21, 11/1997. PMID: 9477134. | |
| 100. | Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 27(3-4):195-205, 10/1997. PMID: 9402319. | |
| 101. | Clodi K, Younes A, Goodacre A, Roberts M, Palmer J, Younes M, Cabanillas F, Andreeff M. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol 98(4):913-21, 9/1997. PMID: 9326189. | |
| 102. | Shade RJ, Younes A. In vitro and in vivo biologic effects of interleukin-3 (IL-3) in follicular low-grade lymphoma. Leuk Lymphoma 26(1-2):17-25, 6/1997. PMID: 9250783. | |
| 103. | Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 26(1-2):77-82, 6/1997. PMID: 9250790. | |
| 104. | Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 96(2):328-32, 2/1997. PMID: 9029021. | |
| 105. | Younes A, Zhao S, Zhang X, Snell V, Clodi K, Kliche KO, Thomas E, Cabanillas F, Andreeff M. CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Ann Oncol 8 Suppl 2:97-100, 1997. PMID: 9209650. | |
| 106. | Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol 8 Suppl 1:129-31, 1997. PMID: 9187446. | |
| 107. | Younes A, Cabanillas F, McLaughlin PW, Hagemeister FB, Farber C, Sarris A, Pate O, Myers J, Portlock C. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol 7(10):1083-5, 12/1996. PMID: 9037370. | |
| 108. | Younes A, Consoli U, Zhao S, Snell V, Thomas E, Gruss HJ, Cabanillas F, Andreeff M. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 93(3):569-71, 6/1996. PMID: 8652374. | |
| 109. | McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14(4):1262-8, 4/1996. PMID: 8648382. | |
| 110. | Younes A, Sarris A, Consoli U, Rodriguez A, McLaughlin P, Huh Y, Starry S, Cabanillas F, Andreeff M. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood 87(5):1698-703, 3/1996. PMID: 8634414. | |
| 111. | Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F, Jr, Romaguera JE, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14(2):543-8, 2/1996. PMID: 8636769. | |
| 112. | Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14(1):233-9, 1996. PMID: 8558203. | |
| 113. | Jendiroba D, Younes A, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study. Leukemia 9(7):1144-6, 7/1995. PMID: 7630187. | |
| 114. | Younes A, Jendiroba D, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization. Cancer Genet Cytogenet 82(1):23-9, 7/1995. PMID: 7627930. | |
| 115. | Touroutoglou N, Dimopoulos MA, Younes A, Hess M, Pugh W, Cox J, Cabanillas F, Sarris AH. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 13(6):1361-7, 6/1995. PMID: 7751880. | |
| 116. | Younes A, Zhao S, Jendiroba D, Kleine HD, Cabanillas F, Andreeff M. Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma. Blood 85(10):2813-6, 5/1995. PMID: 7742542. | |
| 117. | Sarris AH, Majlis A, Dimopoulos MA, Younes A, Swann F, Rodriguez MA, McLaughlin P, Cabanillas F. Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Leuk Lymphoma 17(5-6):473-7, 5/1995. PMID: 7549840. | |
| 118. | Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13(3):583-7, 3/1995. PMID: 7884419. | |
| 119. | Moore DF, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol) 7(5):300-3, 1995. PMID: 8580055. | |
| 120. | Suki S, Swan Jr F, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, Sarris AH, Younes A, Cabanillas F. Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase. Leukemia & Lymphoma 18:87-92, 1995. | |
| 121. | Younes A, Drach J, Katz R, Jendiroba D, Sabourian MH, Sarris AH, Swan F, Jr, Hill D, Cabanillas F, Ford R, et al. Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3. Ann Oncol 5(3):265-8, 3/1994. PMID: 7514436. | |
| 122. | Younes A, Pugh W, Goodacre A, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. Genes Chromosomes Cancer 9(3):161-7, 3/1994. PMID: 7515657. | |
| 123. | Seymour JF, Younes A, Cabanillas F. Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman. Leuk Lymphoma 12(5-6):471-6, 2/1994. PMID: 8180610. | |
| 124. | Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF, Jr, Sarris AH, Younes A, Hill D, Cabanillas F. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs 12(3):217-22, 1994. PMID: 7896540. | |
| 125. | McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5 Suppl 2:73-7, 1994. PMID: 7515650. | |
| 126. | Younes A, Jendiroba D, Engel E, Escudier S, Khoury P, Katz R, Hill D, Rodriguez MA, Cabanillas F, Andreeff M. Monosomy 18 is more common in lymphoid malignancies with high incidence of bone marrow and peripheral blood involvement. Cancer Genet Cytogenet 77:39-44, 1994. | |
| 127. | Romaguera JE, Sarris AH, Swan F, Younes A, Hagemeister FB, McLaughlin P, Rodriguez MA, Moore DF, Cabanillas F. Phase II study of 5-Fluorouracil by protracted infusion in patients with relapsing or refractory lymphoma. J Infusional Chemotherapy 4:173-176, 1994. | |
| 128. | Kurie JM, Younes A, Miller WH, Jr, Burchert M, Chiu CF, Kolesnick R, Dmitrovsky E. Retinoic acid stimulates the protein kinase C pathway before activation of its beta-nuclear receptor during human teratocarcinoma differentiation. Biochim Biophys Acta 1179(2):203-7, 11/1993. PMID: 8218362. | |
| 129. | Mathias S, Younes A, Kan CC, Orlow I, Joseph C, Kolesnick RN. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 259:519-22, 1/1993. PMID: 8424175. | |
| 130. | Younes A, Kemeny N, Kurtz RC, Botet J. Sclerosing cholangitis due to intra-arterial hepatic infusion with chemotherapy: management with non-surgical biliary drainage. Reg Cancer Treat 2:73-76, 1993. | |
| 131. | Michaeli J, Busquets X, Orlow I, Younes A, Colomer D, Marks PA, Rifkind RA, Kolesnick RN. A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis. J Biol Chem 267(33):23463-6, 11/1992. PMID: 1429688. | |
| 132. | Kemeny N Younes A. Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience. Semin Oncol 19(2 Suppl 3):171-5, 4/1992. PMID: 1557642. | |
| 133. | Younes A, Kahn DW, Besterman JM, Bittman R, Byun HS, Kolesnick RN. Ceramide is a competitive inhibitor of diacylglycerol kinase in vitro and in intact human leukemia (HL-60) cells. J Biol Chem 267(2):842-7, 1/1992. PMID: 1309777. | |
| 134. | Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L, Derby S, Murray P, Houston C. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 66(12):2470-5, 12/1990. PMID: 2249187. | |
Invited Articles | ||
| 1. | Wang M Younes A. Testicular Lymphoma: A mysterious link between the testis and the brain. Clin Lymphoma 3(3):173-174, 2002. PMID: 12521395. | |
| 2. | Seymour JF Younes A. Important chromosomal translocations in non-Hodgkin's lymphomas: A review. Diag Oncol 4:12-17, 1994. | |
Editorials | ||
| 1. | Nathan Fowler and Anas Younes. There will be blood: targeting tumor vasculature. Blood 113(10):2121-2122, 3/2009. PMID: 19264922. | |
| 2. | Yasuhiro Oki and Anas Younes. Endothelial progenitor cells in non-Hodgkin’s lymphoma. Haematologica 92:433-34, 4/2007. | |
| Other Articles | ||
| 1. | Younes A. Aggressive Lymphoma. PIER: Online interactive review publication for the American College of Physicians, 2000. | |
Abstracts | ||
| 1. | Michelle A. Fanale, Luis E. Fayad, Barbara Pro, Felipe Samaniego, Gracy Zachariah, Cesar A. Nunez, Yuan Ji, and Anas Younes. A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 112:3048, 11/2008. | |
| 2. | Daniela Buglio, Noor M Khaskhely, George V Georgakis, and Anas Younes. Differential Effect of the Histone Deacetylase Inhibitors Vorinostat and MGCD0103 in Cell-Free and Cell-Based Assays. Blood (ASH Annual Meeting Abstracts) 112:4827, 11/2008. | |
| 3. | Jonathan W. Friedberg, Anas Younes, David C. Fisher, Leo I. Gordon, Joseph O. Moore, Myron S. Czuczman, Thomas P. Miller, Patrick J. Stiff, Bruce D. Cheson, Andres Forero-Torres, Byron McKinney, and John P. Leonard. Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. Blood (ASH Annual Meeting Abstracts) 112:1004, 11/2008. | |
| 4. | Anas Younes, Jonathan Zalevsky, Kristie A. Blum, Mitchell R Smith, Henry C. Fung, David A Ramies, Chris E Lawrence, Daniel Combs, and Jeffrey Bloss. Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 112:5012, 11/2008. | |
| 5. | Paul A. Hamlin, Carol Aghajanian, David Hong, Anas Younes, Michael A. Palladino, Angie M. Longenecker, Gillian Cropp, G. Kenneth Lloyd, Alison L. Hannah, Matthew A. Spear, and Razelle Kurzrock. First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor. Blood (ASH Annual Meeting Abstracts) 112:4939, 11/2008. | |
| 6. | Michael Wang, Liang Zhang, Luis Fayad, Fredrick Hagemeister, Sattva Neelapu, Felipe Samaniego, Barbara Pro, Anas Younes, Scott Miller, Robert D. Knight, Jerome B. Zeldis, Qing Yi, and Jorge Romaguera. Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 112:3058, 11/2008. | |
| 7. | Anas Younes, Andres Forero-Torres, Nancy L. Bartlett, John P. Leonard, Carmel Lynch, Dana A. Kennedy, and Eric Sievers. Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas. Blood (ASH Annual Meeting Abstracts) 112:1006, 11/2008. | |
| 8. | Felipe Samaniego, Michelle Fanale, Barbara Pro, F.B. Hagemeister, Peter McLaughlin, Jorge Romaguera, Sattva Neelapu, Maria Alma Rodriguez, Luis Fayad, Anas Younes, and Larry W. Kwak. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression. Blood (ASH Annual Meeting Abstracts) 112:835, 11/2008. | |
| 9. | Peter McLaughlin, Sattva Neelapu, Michelle Fanale, Maria Rodriguez, Ana Ayala, Barbara Pro, F.B. Hagemeister, Anas Younes, Susan Neel, Nathan Fowler, Mark Hess, and Larry W. Kwak. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 112:3056, 11/2008. | |
| 10. | Jorge Romaguera, Luis Fayad, Alma Rodriguez, Fb Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Jatin Shah, Pamela Weaver, Kim Hartig, Fernando Cabanillas, Larry Kwak, Hagop Kantarjian, and Michael Wang. Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 112:833, 11/2008. | |
| 11. | R. G. Bociek, J. Kuruvilla, B. Pro, A. Wedgwood, Z. Li, M. Drouin, T. Patterson, R. Ward, R. E. Martell, and A. Younes. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). ASCO Meeting Abstracts 26:8507, 5/2008. | |
| 12. | K. Suh, P. McLaughlin, J. E. Romaguera, F. B. Hagemeister, B. Pro, I. F. Khouri, F. Samaniego, M. A. Rodriguez, L. E. Fayad, L. Feng, and A. Younes. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. ASCO Meeting Abstracts 26:8599, 5/2008. | |
| 13. | A. Younes, A. Forero-Torres, N. L. Bartlett, J. P. Leonard, B. Rege, D. A. Kennedy, J. M. Lorenz, and E. L. Sievers. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. ASCO Meeting Abstracts 26:8526, 5/2008. | |
| 14. | C. A. Aghajanian, P. Hamlin, M. S. Gordon, D. S. Hong, A. Naing, A. Younes, A. Hannah, M. A. Palladino, M. A. Spear, and R. Kurzrock. Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors. ASCO Meeting Abstracts 26:3574, 5/2008. | |
| 15. | ASCO Meeting Abstracts. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin’s lymphomas. ASCO Meeting Abstracts 26:8589, 5/2008. | |
| 16. | M. Crump, C. Andreadis, S. Assouline, D. Rizzieri, A. Wedgwood, P. McLaughlin, E. Laille, Z. Li, R. E. Martell, and A. Younes. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. ASCO Meeting Abstracts 26:8528, 5/2008. | |
| 17. | Nancy L. Bartlett, Anas Younes, Matthew H. Carabasi, Andres Forero, Joseph D. Rosenblatt, John P. Leonard, Steven H. Bernstein, R. Gregory Bociek, Jennie M. Lorenz, Bruce W. Hart, and Jeremy Barton. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111(4):1848-1854, 2/2008. e-Pub 12/13/2007. PMID: 18079362. | |
| 18. | Nancy L. Bartlett, Anas Younes, Matthew H. Carabasi, Andres Forero, Joseph D. Rosenblatt, John P. Leonard, Steven H. Bernstein, R. Gregory Bociek, Jennie M. Lorenz, Bruce W. Hart, and Jeremy Barton. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111:1848-1854, 2/2008. | |
| 19. | Anas Younes, Barbara Pro, Michelle Fanale, Peter McLaughlin, Sattva Neelapu, Luis Fayad, Amanda Wedgwood, Daniela Buglio, Tracy Patterson, Marja Dubay, Zuomei Li, Robert E. Martell, M. Renee Ward, and R. Gregory Bociek. Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts) 110:2566, 11/2007. | |
| 20. | Razelle Kurzrock, Paul Hamlin, Anas Younes, David Hong, Michael Gordon, Matthew A. Spear, Michael A. Palladino, G. Kenneth Lloyd, Angie M. Longenecker, Saskia T.C. Neuteboom, Gillian F. Cropp, Alison Hannah, and Carol Aghajanian. Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors. Blood (ASH Annual Meeting Abstracts) 110:4504, 11/2007. | |
| 21. | Barbara Pro, Luis Fayad, Jorge Romaguera, Michelle Fanale, Anas Younes, Fredrick B. Hagemeister, Felipe Samaniego, Peter McLaughlin, M.A. Rodriguez, Larry Kwak, and Nam H. Dang. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 110:3456, 11/2007. | |
| 22. | Amanda R. Wedgwood, Michelle A. Fanale, Luis E. Fayad, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Jorge Romaguera, Maria A. Rodriguez, Felipe Samaniego, and Anas Younes. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. Blood (ASH Annual Meeting Abstracts) 110:215, 11/2007. | |
| 23. | Michelle A. Fanale, Luis Fayad, Barbara Pro, Felipe Samaniego, Gracy Zachariah, Cesar A. Nunez, Yuan Ji, and Anas Younes. Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma. Blood (ASH Annual Meeting Abstracts) 110:4506, 11/2007. | |
| 24. | Michael J. Overman, Lei Feng, Barbara Pro, Peter McLaughlin, Mark Hess, Felipe Samaniego, Anas Younes, Jorge E. Romaguera, Frederick B. Hagemeister, Larry Kwak, Fernando Cabanillas, Maria A. Rodriguez, and Luis E. Fayad. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood (ASH Annual Meeting Abstracts) 110:1289, 11/2007. | |
| 25. | Anas Younes, Amanda Wedgwood, Peter McLaughlin, Charalambos Andreadis, Sarit E. Assouline, Zuomei Li, Robert E. Martell, Marja Dubay, Tracy-Ann Patterson, Michelle R. Ward, and Michael Crump. Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study. Blood (ASH Annual Meeting Abstracts) 110:2571, 11/2007. | |
| 26. | Daniela Buglio, Georgios Georgakis, Kazuhiko Arima, Yong-Jun Liu, and Anas Younes. Vorinostat (SAHA) Inhibits STAT6 Phosphorylation and Transcription, Downregulates Bcl-xL, and Induces Apoptosis in Hodgkin Lymphoma (HL) Cell Lines. Blood (ASH Annual Meeting Abstracts) 110:380, 11/2007. | |
| 27. | Razelle Kurzrock, Paul Hamlin, Anas Younes, David Hong, Michael Gordon, Alison Hannah, Michael Palladino, G. Kenneth Lloyd, Angie Longenecker, Saskia Neuteboom, Gillian Cropp, Matthew Spear, and Carol Aghajanian. Results from phase 1 dose escalation study of the proteasome inhibitor NPI-0052 in patients with solid tumors and lymphomas. AACR Meeting Abstracts 2007:B1, 10/2007. | |
| 28. | A. Younes, M. Fanale, B. Pro, P. McLaughlin, S. Neelapu, L. Fayad, A. Wedgwood, M. Dubay, J. Backstrom, and R. E. Martell. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. ASCO Meeting Abstracts 25(18S (June 20 Supplement)):8000, 6/2007. | |
| 29. | M. S. Cairo, M. Cornelis, A. Baruchel, A. Bosly, B. Cheson, C. Pui, J. M. Ribera, S. Rule, A. Younes, and B. Coiffier. Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): International expert panel analysis. ASCO Meeting Abstracts 25:17006, 6/2007. | |
| 30. | Buglio Daniela, Georgios Georgakis, Victor Yazbeck, Ta-Hsiang Chao, Saskia Neuteboom, Michael Palladino, and Anas Younes. A novel proteasome inhibitor, NPI-0052 is active in Hodgkin and Mantle cell lymphoma cell lines. AACR Meeting Abstracts 2007:1454, 4/2007. | |
| 31. | Jorge Enrique Romaguera, Luis Fayad, Maria Alma Rodriguez, F.B. Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Andreas H. Sarris, Nam H. Dang, Luhua Wang, Hagop M. Kantarjian, Virginia Beasley, L. Jeffrey Medeiros, Ruth L. Katz, and Fernando Cabanillas. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood (ASH Annual Meeting Abstracts) 108:2749, 11/2006. | |
| 32. | Issa F. Khouri, Rima M. Saliba, Chitra Hosing, Rosamar Valverde, William D. Erwin, Luis Fayad, Farzaneh Maadani, Martin J. Korbling, Grace-Julia Okoroji, Anne M. Stachowiak, Barry I. Samuels, Paolo Anderlini, Daniel R. Couriel, Marcos de Lima, Sergio Giralt, Uday Popat, Partow Kebriaei, Naoto T. Ueno, Muzaffar H. Qazilbash, Peter W. McLaughlin, Fredrick B. Hagemeister, Anas Younes, Donald A. Podoloff, and Richard E. Champlin. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 108:315, 11/2006. | |
| 33. | Luis Fayad, Michael Overman, Barbara Pro, Peter McLaughlin, Felipe Samaniego, Anas Younes, Jorge Enrique Romaguera, F.B. Hagemeister, Larry Kwak, and Maria Alma Rodriguez. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood (ASH Annual Meeting Abstracts) 108:2770, 11/2006. | |
| 34. | Victor Y. Yazbeck, Georgios V. Georgakis, Yang Li, David McConkey, Michael Andreeff, and Anas Younes. Inhibition of the Pan-Bcl-2 Family by the Small Molecule GX15-070 Induces Apoptosis in Mantle Cell Lymphoma (MCL) Cells and Enhances the Activity of Two Proteasome Inhibitors (NPI-0052 and Bortezomib), and Doxorubicin Chemotherapy. Blood (ASH Annual Meeting Abstracts) 108:2532, 11/2006. | |
| 35. | V. Y. Yazbeck, G. V. Georgakis, Y. Li, and A. Younes. Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy, and Synergy with Vorinostat (SAHA). Blood (ASH Annual Meeting Abstracts) 108:2493, 11/2006. | |
| 36. | Felipe Samaniego, Luis E. Fayad, Barbara Pro, Peter McLaughlin, Maria Alma Rodriguez, F.B. Hagemeister, Michelle Fanale, Sattva Neelapu, Anas Younes, and Larry W. Kwak. Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 108:4722, 11/2006. | |
| 37. | Michael Wang, Yasuhiro Oki, Barbara Pro, Jorge Enrique Romaguera, Maria Alma Rodriguez, Felipe Samaniego, Peter McLaughlin, Frederick Hagemeister, Sattva Neelapu, Donald Podoloff, Barry Samuels, Evelyne Loyer, Yuhong Zhou, and Anas Younes. Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 108:2714, 11/2006. | |
| 38. | Anas Younes, Luis Y. Fayad, Andre Goy, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Fredrick Hagemeister, Maria A. Rodriguez, Felipe Samaniego, Larry Kwak, Sattva Neelapu, L. Jeffrey Medeiros, Amanda Wedgwood, and Michelle Fanale. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood (ASH Annual Meeting Abstracts) 108:2742, 11/2006. | |
| 39. | Ranjana Advani, Andres Forero-Torres, Richard R. Furman, Joseph D. Rosenblatt, Anas Younes, Brooke Shankles, Kate Harrop, and Jonathan G. Drachman. SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study. Blood (ASH Annual Meeting Abstracts) 108:695, 11/2006. | |
| 40. | Georgios V. Georgakis, Victor Y. Yazbeck, Yang Li, and Anas Younes. The Histone Deacetylase Inhibitor Vorinostat (SAHA) Induces Apoptosis and Cell Cycle Arrest in Hodgkin Lymphoma (HL) Cell Lines by Altering Several Survival Signaling Pathways and Synergizes with Doxorubicin, Gemcitabine and Bortezomib. Blood (ASH Annual Meeting Abstracts) 108:2260, 11/2006. | |
| 41. | Georgios V. Georgakis, Victor Y. Yazbeck, Yang Li, and Anas Younes. The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002. Blood (ASH Annual Meeting Abstracts) 108:2259, 11/2006. | |
| 42. | A. Forero-Torres, R. R. Furman, J. D. Rosenblatt, A. Younes, K. Harrop, J. G. Drachman, and R. Advani. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin’s lymphoma (NHL): Results of a phase I study. ASCO Meeting Abstracts 24:7534, 6/2006. | |
| 43. | G. V. Georgakis, V. Y. Yazbeck, Y. Li, and A. Younes. Preclinical rationale for therapeutic targeting of mTOR by CC-I779 and rapamycin in Hodgkin lymphoma. ASCO Meeting Abstracts 24:10070, 6/2006. | |
| 44. | V. Y. Yazbeck, G. V. Georgakis, Y. Li, and A. Younes. The mTOR inhibitor CCI-779 (temsirolimus) downregulates p21 and induces cell cycle arrest and autophagy in mantle cell lymphoma (MCL). ASCO Meeting Abstracts 24:7573, 6/2006. | |
| 45. | Xia Tong, Sharon Lea Aukerman, Karen Lin, Natasha Aziz, Cheryl Goldbeck, Georgios V. Georgakis, Anas Younes, Wen-Kai Weng, Susan O’Brien, William Wierda, Bahija Jallal, and Mohammad Luqman. A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells. Blood (ASH Annual Meeting Abstracts) 106:2964, 11/2005. | |
| 46. | Ranjana H. Advani, Richard R. Furman, Joseph D. Rosenblatt, Anas Younes, Andres Forero-Torres, Kate L. Harrop, Karen T. Baumgartner, Michael McDonald, and Jonathan G. Drachman. A Phase I Study of Humanized Anti-CD40 Immunotherapy with SGN-40 in Non-Hodgkin’s Lymphoma. Blood (ASH Annual Meeting Abstracts) 106:1504, 11/2005. | |
| 47. | Anas Younes, Jorge E. Romaguera, Peter McLaughlin, and Franklin Wong. A Pilot Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma (HL): Delivering Cross Fire Radiation by Targeting Reactive B Cells in the Microenvironment. Blood (ASH Annual Meeting Abstracts) 106:4791, 11/2005. | |
| 48. | Anas Younes, Luis Fayad, Jorge E. Romaguera, Barbara Pro, and Michael Wang. ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study. Blood (ASH Annual Meeting Abstracts 106:4790, 11/2005. | |
| 49. | Anas Younes, Barbara Pro, Maria A. Rodriguez, Jorge E. Romaguera, Peter McLaughlin, Michael Wang, Fredrick B. Hagemeister, Nam H. Dang, Sattva Neelapu, and Donald Podoloff. Activity of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 106:2452, 11/2005. | |
| 50. | Issa F. Khouri, Rima M. Saliba, Chitra M. Hosing, Sandra A. Acholonu, Luis E. Fayad, Martin J. Korbling, Celina Saenz, Barbara Pro, Barry I. Samuels, Marcos J. de Lima, Sergio A. Giralt, Anas Younes, Peter W. McLaughlin, and Richard E. Champlin. Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL). Blood (ASH Annual Meeting Abstracts) 106:48, 11/2005. | |
| 51. | Daniela Buglio, Noor M Khaskhely, George V Georgakis, and Anas Younes. Differential Effect of the Histone Deacetylase Inhibitors Vorinostat and MGCD0103 in Cell-Free and Cell-Based Assays. Blood (ASH Annual Meeting Abstracts) 106:1361, 11/2005. | |
| 52. | Anas Younes, Luis Fayad, Barbara Pro, Andre Goy, Jorge E. Romaguera, Fredrick B. Hagemeister, and Peter McLaughlin. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 106:1498, 11/2005. | |
| 53. | Georgios V. Georgakis, Yang Li, George Z. Rassidakis, Felipe Samaniego, L. Jeffrey Medeiros, and Anas Younes. Heat Shock Protein 90 (HSP90) Inhibition by the Small Molecule 17-AAG Induces Cell Cycle Arrest and Apoptosis in Anaplastic Large Cell Lymphoma (ALCL) Irrespective of ALK Expression: Role of Akt, ERK and ALK Kinases in the Molecular Mechanisms of 17-AAG Anti-Tumor Activity. Blood (ASH Annual Meeting Abstracts) 106:2811, 11/2005. | |
| 54. | Georgios V. Georgakis, Yang Li, George Z. Rassidakis, L. Jeffrey Medeiros, and Anas Younes. Heat Shock Protein 90 (HSP90) Is Overexpressed in Primary and Cultured Hodgkin Lymphoma (HL) Cells: Role of Therapeutic Targeting Using the Small Molecule Inhibitor 17-AAG. Blood (ASH Annual Meeting Abstracts) 106:2422, 11/2005. | |
| 55. | Jorge Enrique Romaguera, Luis E. Fayad, Michael Wang, Fernando Cabanillas, Fredrick Hagemeister, Peter McLaughlin, Alma Rodriguez, Anas Younes, Sattva Neelapu, Andre H. Goy, Virginia Beasley, and Larry Kwak. High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A). Blood (ASH Annual Meeting Abstracts) 106:2446, 11/2005. | |
| 56. | Felipe Samaniego, Shu Wang, Daniel Young, Anas Younes, and Suizhao Wang. Human Herpesvirus 8 K1 Suppresses Fas-Mediated Apoptosis and Binds to the Fas Complex. Blood (ASH Annual Meeting Abstracts) 106:1361, 11/2005. | |
| 57. | Nam H. Dang, Peter McLaughlin, Luis Fayad, Jorge Romaguera, Fredrick Hagemeister, Anas Younes, Sattva Neelapu, Felipe Samaniego, Dan Jones, Pamela L. Walker, Maria A. Rodriguez, Larry Kwak, and Barbara Pro. Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma. Blood (ASH Annual Meeting Abstracts) 106:3349, 11/2005. | |
| 58. | Issa F. Khouri, Rima M. Saliba, Ming-Sheng Lee, Grace-Julia Okoroji, Luis Fayad, Farzaneh Maadani, Chitra Hosing, Barry Samuels, Sergio Giralt, Marcos de Lima, Barbara Pro, Anas Younes, Peter McLaughlin, Larry Kwak, and Richard E. Champlin. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Blood (ASH Annual Meeting Abstracts) 106:44, 11/2005. | |
| 59. | Nam H. Dang, Barbara Pro, Fredrick Hagemeister, Felipe Samaniego, Dan Jones, Maria Rodriguez, Andre Goy, Jorge Romaguera, Pamela L. Walker, Anas Younes, Sattva Neelapu, Larry Kwak, and Luis Fayad. Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood (ASH Annual Meeting Abstracts) 106:3350, 11/2005. | |
| 60. | Maria Alma Rodriguez, Nam H. Dang, Luis Fayad, Andre Goy, Fredrick Hagemeister, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Anas Younes, and Fernando Cabanillas. Phase II Study of Sphingosomal Vincristine in CHOP+/ – Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients. Blood (ASH Annual Meeting Abstracts) 106:943, 11/2005. | |
| 61. | Yasuhiro Oki, Georgios V. Georgakis, Thi-Sau Migone, Larry W. Kwak, and Anas Younes. Serum BLyS Level as a Prognostic Marker in Patients with Lymphoma. Blood (ASH Annual Meeting Abstracts) 106:1926, 11/2005. | |
| 62. | Anas Younes, Peter McLaughlin, Luis E. Fayad, Andre Goy, Jorge E. Romaguera, Barbara Pro, Maria A. Rodriguez, Felipe Samaniego, Larry Kwak, Sattva Neelapu, and Jeffrey Medeiros. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab. Blood (ASH Annual Meeting AbstractS) 106:1499, 11/2005. | |
| 63. | Luis Fayad, Barbara Pro, Qi Liu, Mark Hess, Fredrick Hagemeister, Jorge Romaguera, Felipe Samaniego, Fernando Cabanillas, Alma Rodriguez, Anas Younes, Michael Wang, and Peter McLaughlin. Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). Blood (ASH Annual Meeting Abstracts 106:933, 11/2005. | |
| 64. | Jonathan W. Friedberg, John P. Leonard, Anas Younes, David C. Fisher, Leo I. Gordon, Joseph O. Moore, Myron S. Czuczman, Thomas P. Miller, Patrick J. Stiff, Bruce D. Cheson, Andres Forero-Torres, Deborah M. Finucane, Bryan R. Leigh, and Arturo Molina. Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL. Blood (ASH Annual Meeting Abstracts) 106:2435, 11/2005. | |
| 65. | Pro B, Smith R, Leber B, Younes A, Fayad L, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y. Phase II Study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-cell non-Hodgkin’s Lymphoma. ASCO Meeting Abstracts 23:6611 (#6611), 6/2005. | |
| 66. | G. V. Georgakis, Y. Li, and A. Younes. Preclinical evaluation of the HSP-90 inhibitor 17AAG in Hodgkin’s and non-Hodgkin’s lymphomas: Induction of apoptosis and potentiation of chemotherapy cytotoxicity. ASCO Meeting Abstracts 23:6570, 6/2005. | |
| 67. | L. Fayad, J. Romaguera, S. Hart, A. Younes, B. Pro, F. Hagemeister, P. McLaughlin, N. Dang, A. Pretti, A. Sarris, and F. Gil. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. ASCO Meeting Abstracts 23:6624, 6/2005. | |
| 68. | J. P. Leonard, A. Younes, J. D. Rosenblatt, A. Gopal, L. C. Pinter-Brown, N. L. Bartlett, L. J. Burns, A. Forero, and J. Barton. Targeting CD30 as therapy for Hodgkin’s disease. Phase II results with the monoclonal antibody SGN-30. ASCO Meeting Abstracts 23:2553, 6/2005. | |
| 69. | Jose R. Valbuena, Coralyn Atwell, Georgios V. Georgakis, Anas Younes, L. Jeffrey Medeiros, and George Z. Rassidakis. SGN-30, a novel chimeric anti-CD30 antibody, induces cell cycle arrest and apoptosis in ALK+ anaplastic large cell lymphoma. AACR Meeting Abstracts 2005:104-5, 4/2005. | |
| 70. | Jose R. Valbuena, Coralyn Atwell, Georgios V. Georgakis, Anas Younes, L. Jeffrey Medeiros, and George Z. Rassidakis. SGN-30, a novel chimeric anti-CD30 antibody, induces cell cycle arrest and apoptosis in ALK+ anaplastic large cell lymphoma. AACR Meeting Abstracts 2005:104-105, 4/2005. | |
| 71. | Younes A, Rodriguez M, Pro B, McLaughlin P, Romaguera J, Hagemeister F, Wang M. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v96 (#201), 2005. | |
| 72. | Pro B, Leber B, Smith M, Younes A, Fayad L, Hagemeister F, McLaughlin P, Rodriguez M, Kwak LW, Caddick Y, Zwiebel J. A Phase II Trial of Oblimersen Sodium (G3139) Plus Rituximab for Treatment of Patients with Recurrent B-Cell Non-Hodgkin’s Lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v68 (#103), 2005. | |
| 73. | Woodworth J, Hom Peltz E, Leonard JP, Friedberg J, Younes A, Fisher D,Gordon L, Leigh BR. Galiximab Pharmacokinetics Determined in Patients with Relapsed or Refractory Follicular NHL. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v208 (#585), 2005. | |
| 74. | Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, Medeiros L, Katz R, Gagneja H, Samuels B, Cabanillas F. High Rates of Failure-Free Survival (FFS) and Overall Survival (OS) in Untreated Mantle Cell Lymphoma (MCL) after Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-dose Methotrexate-Cytarabine (R-M/A). . Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v95 (#197), 2005. | |
| 75. | Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dand N, Samaniego F, Rodriguez M, Fayad L. Paclitaxel Plus Topotecan Plus Rituximab (TTR): An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v101 (#220), 2005. | |
| 76. | Fayad L, Romaguera JE, Hart S, Younes A, Pro B, Hagemeister FB, McLaughlin P, Dang N, Preti A, Sarris A, Gil F. Report of Sphingosomal Vincristine (SV) in patients with Relapsed or Refractory Hodgkin’s Disease. ASCO Proceedings 23:591s (#6624), 2005. | |
| 77. | Leonard J, Friedberg J, Younes A, Fisher D, Gordon L, Moore J, Czuczman M, Miller T, Stiff P, Cheson B, Forero-Torres A, Nasizadeh H, Whiteley M, Leigh BR. Results from a Phase I/II Study of Galiximab (Anti-CD80) in Combination with Rituximab (Anti-CD20) for Relapsed or Refractory, Follicular NHL. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v71 (#115), 2005. | |
| 78. | Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin Lymphoma: A Novel Combination Program Targeting the Cancer Cells and the Reactive B-Cells in the Microenvironment. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v196 (#545), 2005. | |
| 79. | Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Safety and Efficacy of Single Fixed Dose Pegfilgrastim (Neulasta) in Chemotherapy Regimens Given Every 14 Days:Results of ABVD Plus Pegfilgratism in Patients with Hodgkin Lymphoma. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v196 (#546), 2005. | |
| 80. | McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros L, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F. Stage IV Indolent Lymphoma: A Randomized Trail of Concurrent Vs. Sequential FND (Fludarabine, Mitoxantrone, Dexamethasone) and Rituximab, with Interferon Maintenance. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v109 (#247), 2005. | |
| 81. | Leonard JP, Younes A, Rosenblatt JD, Gopal a, Pinter-Brown LC, Bartlett NL, Burns LJ, Forero A, Barton J. Targeting CD30 as Therapy for Hodgkin’s Disease. Phase II Results with the Monoclonal Antibody SGN30. ASCO Proceedings 23:179s (#2553), 2005. | |
| 82. | Georgakis G, Li Y, Rassidakis G, Medeiros L, Mills G, Younes A. The Phosphatidylinositol-3 Kinase/AKT Pathway is Aberrantly Active and Promotes Survival of Hodgkin Lymphoma Cells: Implications for Novel Targeted Therapy. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v83 (#158), 2005. | |
| 83. | Georgakis G, Li Y, Rassidakis G, Fayad L, Medeiros L, Younes A. Therapeutic Inhibition of Heat Shock Protein-90 Function in Hodgkin Lymphoma. Proceedings of the 9th International Conference on Malignant Lymphoma. Lugano, Switzerland, Ann Oncol 19(Suppl 5):v215 (#607), 2005. | |
| 84. | Georgakis G, Li Y, Humphreys R, Andreeff M, O’brien S, Younes M, Carbone A, Albert V, Younes A. Triggering of Trail-RI and Trail-R2 Death Receptors by their Selective Fully Human Agonistic Antibodies Induces Apoptosis in Primary and Cultured Lymphoma Cells. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v70 (#110), 2005. | |
| 85. | Oki Y, Pro B, Delpassand E, Ballaster V, McLaughlin P, Romaguera JE, Wang M, Hagemeister FB, Younes A. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). . Blood 104:720a (#2632), 2004. | |
| 86. | Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Younes A, Grimm EA. A Randomized Trial of CHOP Chemotherapy with or without melatonin in Patients with Favorable Pronosis Large B-cell Lymphoma. ASCO Proceedings 22:745s (#8066), 2004. | |
| 87. | Georgakis G, Li Y, Rassidakis G, Medeiros J, Mills G, Younes A. Differential Effects of Three Small Molecules Blocking Phosphatidylinositol-3 Kinase or AKT in Hodgkin Disease Cell Lines: Induction of Apoptosis and Cell Cycle Arrest. Blood 104:125a-126a (#428), 2004. | |
| 88. | Czuczman M, Leigh B, Witzig T, Vose J, Younes A, Alkuzweny B, Larocca A, Cao X, Thall A. Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody). Blood 104:899a-900a (#3292), 2004. | |
| 89. | Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma. Blood 104:245b (#4646), 2004. | |
| 90. | Pro B, Smith MR, Younes A, Fayad LE, Goy A, Hagemeister FB, McLaughlin P, Rodriguez MA, Frankel SR, Zwiebel JA. Oblimersen Sodium (Bcl-2 antisense) plus rituximab in patients with recurrent B-cell non-Hodgkin’s lymphoma: Preliminary Phase II Results. ASCO Proceedings 22:575s (#6572), 2004. | |
| 91. | Thomas D, Cortes J, Faderl S, O’Brien S, Beran M, Koller C, Garcia-Manero G, Younes A, Fayad L, Wierda W, Pierce S, Giles F, Kantarjian H. Outcome with The Hyperc-CVAD and Rituximab Regimen in Burkitt (RL) and Burkitt-Like (BLL) Leukemia/Lymphoma. Blood 104:901a (#3297), 2004. | |
| 92. | Oki Y, McLaughlin P, Pro B, Hagemeister F, Bleyer A, Loyer E, Younes A. Phase II Study of Oxaliplatin in Patients with Relapsed or Refractory Non-Hodgkin’s Lyphoma: Final Results. Blood 104:684a (#2494), 2004. | |
| 93. | Leonard J, Rosenblatt JD, Bartlett NL, Gopal A, Younes A, Fisher D, Foss F, Forrero A, Bernstein S, Cheson B, Carabasi MH, Bociek R, Hart B, McDonald M. Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients With Refractory or Recurrent Hodgkin’s Disease. Blood 104:721a (#2635), 2004. | |
| 94. | Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Medeiros J, Katz R, Gagneja H, Samuels BI, Cabanillas F. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS). . Blood 104:40a (#128), 2004. | |
| 95. | Younes A, Pro B, Romaguera JE, Dang N. Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease. Blood 104:722a (#2638), 2004. | |
| 96. | Georgakis G, Li Y, Robin H, Andreeff M, O’brien S, Albert V, Younes A. Selective Agnostic Monoclonal Antibodies to the TRAIL Receptors R1 and R2 Induce Cell Death Potentiate the Effect of Chemotherapy and Bortezomib in Primary and Cultured Lymphoma Cells. ASCO Proceedings 22:581s (#6595), 2004. | |
| 97. | Forero-Torres A, Bernstein S, Gopal A, Foss F, Leonard J, Rosenblatt J, Bartlett N, Younes A, Fisher D, Cheson B, Carabasi M, Bociek G, Hart B, McDonald M. SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma. Blood 104:721a-722a (#2637), 2004. | |
| 98. | Rodriguez MA, Sarris A, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of Phase II Study. Blood 104:234b (#4602), 2004. | |
| 99. | Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP is a Promising New Treatment for Elderly, as Well as Poor Prognosis Patients with Aggressive non-Hodgkin’s Lymphoma (NHL): Follow-up Results of a Phase II Study. ASCO Proceedings 22:748s (#8080), 2004. | |
| 100. | Georgakis G, Li Y, Younes A. The Geldanamycin Analogue Heat Shock Protein 90 (HSP90) Inhibitor 17-AAG in Lymphomas: Molecular Mechanisms of 17-AAG-Induced Cell Death in Hodgkin Disease and Non-Hodgkin Lymphoma Cell Lines. Blood 104:899a (#3291), 2004. | |
| 101. | Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Fayad, LE, Trehu EG, Schenkein D, Rodriguez MA. Update on a Phase (ph) 2 Study Of Bortezomib in Patients (pts) with Relapsed or Refractory Indolent or Aggressive non-Hodgkin’s lymphomas (NHL). . ASCO Proceedings 22:577s (#6581), 2004. | |
| 102. | Younes A, Fayad LE, Romaguera JE, Pro B, Dang N, Wang M. 5{Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after 170 Consecutive Dose of ABVD Chemotherapy in Patients with Hodgkin Lymphoma: Safety of Pegfilgrastim with q14-Day Chemotherapy Regimens. Blood 102:637a (#2352), 2003. | |
| 103. | Younes A, Pro B, Delpassasand E, McLaughlin P, Romaguera JE, Wang M. A Phase II Study of 90Yttrium-ibritumomab (Zevalin) for the Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). . Blood 102:406a (#1476), 2003. | |
| 104. | Zhang B, Yang Y, Georgakis G, Bharti A, McConkey D, Aggarwal BB, Younes A. Activity of Proteosome Inhibitor PS341 in Hodgkin’s Disease Cell Lines. (ASCO). ASCO Proceedings 22:570, 2003. | |
| 105. | Georgakis G, Li Y, Humphreys R, Johnson R, Andreeff M, Fiscella M, Pukac, L, O’Brien S, Albert V, Younes A. Activity of Selective Agonistic Monoclonal Antibodies to TRAIL Death Receptors R1 and R2 in Primary and Cultured Tumor Cells of Hematological Origin. . Blood 102:228a (#799), 2003. | |
| 106. | Younes A, Pro B, Goy A, Fayad LE, Romaguera JE. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Disease: Depletion of Benign B-Cells from HD Microenvironment by Rituximab May Enhances The Activity of Gemcitabine. Blood 102:412a (#1500), 2003. | |
| 107. | Pro B, Smith M, Younes A, Dang N, Fayad LE, Goy A, Hagemeister FB, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel S, Zwiebel JA. Genasense (BcL-2 Antisense) Plus Rituximab Is Active in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphma. Blood 102:410a (#1491), 2003. | |
| 108. | Khouri I, Saliba R, Acholonu S, Okoroji G, Hosing C, Fayad LE, Couriel D, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin R. Improved Outcome With High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem CellTransplantation (ASCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL):The Impact of Histologies of Follicular (FL) Origin. Blood 102:735a-736a (#2716), 2003. | |
| 109. | Czuczman MS, Younes A, Moore JO, Emmanuoilides C, Witzig TE, Vose JM, Miller TP, Gordon LI, Leigh BR. Interim results from a phase 1/11 phase study of anti-CD80 antibody (IDEC-114) therapy for follicular NHL. ASCO Proceedings 22:574, 2003. | |
| 110. | Cabanillas ME, Thomas DA, Cortes J, Faderl S, O’Brien S, Beran M, Younes A, Fayad L, Koller C, Kantarjian H. Outcome with hyper-CVAD and rituximab in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma. ASCO Proceedings 22:574, 2003. | |
| 111. | Carabasi MA, Bartlett NL, Younes A, Miller DM, Schliebner SD, Siegall, CB, Sing AP. Pharmacokinetics, safety, and tolerability of SGN-20, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies. ASCO Proceedings 22:180, 2003. | |
| 112. | Younes A, McLaughlin P, Pro B, Hagemeister FB, Bleyer A. Phase II Study of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma (NHL). Blood 102:639a-640a (#2361), 2003. | |
| 113. | Goy A, Hart S, Tiongson L, Fayad LE, Romaguera JE, Younes A, Dang N, Pretti A, Samuels B, Sarris A, Gilles F, Rodriguez MA. Preliminary Report of a Phase II Study Of Vincristine Sulfate Liposomes Injection (VSLI) in Patients with Relapsed or Refractory Hodgkin’s Disease. Blood 102:640a (#2362), 2003. | |
| 114. | Georgakis G, Zhang B, Li Y, Bharti A, McConkkey D, Aggarwal B, Younes A. Proteasome Inhibitor Botezomib (PS341, VELCADE) Induces Cell Cycle Arrest and Caspase-Mediated Apoptosis in Hodgkin Disease (HD) Cell Lines:Relatively for Clinical Evaluation in Patients with Relapsed HD. Blood 102:890a (#3313), 2003. | |
| 115. | Rodriguez MA, Besien K, Hagemeister FB, Giralt S, McLaughlin P, Gajewski, JL, Romaguera JE, Khouri I, Younes A, Cabanillas F, Champlin R. Randomized Comparison of Frontline Alternating Chemotherapy (ATT) Version Brief Induction Followed by Autologous Stem Cell Transplant (ASCT) for Aggressive Lymphomas. Blood 102:402a (#1458), 2003. | |
| 116. | Goy A, Hart S, Pro B, McLaughlin P, Younes A, Dang N, Fayad LE, Romaguera JE, Cabanillas F, Hagemeister FB, Samaniego F, Wang M, Mesina O, Gilles F, Trehu E, Shenkein D. Report of a Phase II Study of Proteasome Inhibitor Bortezomib (VELCADETM) in Patients with Relapsed or Refractory Indolent or Aggressive Lymphomas. Blood 102:180a (#627), 2003. | |
| 117. | Goy A, East K, Mesina O, Cabanillas F, Fayad L, Hagemeister FB, Romaguera J, Scheinken D, Trehu E, Wang M, Younes A, Gilles F, Rodriguez A. Report of a phase II study of proteasomme inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas. ASCO Proceedings 22:570, 2003. | |
| 118. | Czuzman M, Witzig T, Vose J, Younes A, Emmanouilides C, Miller T, Moore, J, Leonard J, Gordon L, Finucane D, Whiteley M. Results of a Phase I/II Multicenter Trial of Galiximab (IDEC-114, Anti-CD80 Antibody) Therapy for Relapsed or Refractory Follicular Lymphoma. Blood 102:647a-648a (#2393), 2003. | |
| 119. | Younes A, McLaughlin P, Goy A, Medeiros J, Jones D, Fayad L, Abruzzo L, Pro B. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease: A Novel Combination Program Targeting the Cancer Cells and The Microenvironment. Blood 102:27a (#83), 2003. | |
| 120. | Younes A, Fayad LE, Pro B, McLaughlin P, Hagemeister FB, Mansfield P, Clayman G, Medeiros LJ, Lewis J, Srivastava P. Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine in Low-Grade Lymphoma. (ASCO). ASCO Proceedings 22:570, 2003. | |
| 121. | Barlett NL, Bernstein S, Leonard J, Rosenblatt J, Younes A, Carabasi M, Bociek G, Forero A, Miller D, Siegall C, Sing A. Safety, Antitumor Activity and Pharmacokinetics of Six Weekly Doses of SGN-30 (anti-CD30 Monoclonal Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. Blood 102:647a (#2390), 2003. | |
| 122. | Rodriguez MA, Hagemeister FB, Romaguera J, Sarris AH, Younes A, Dang NH, Goy A, Samaniego F, Hess M, others. Stage IV. Stage IV indolent lymphomas; a randomized study of concurrent vs sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab ® monoclonal antibody therapy, with interferon maintenance . ASCO Proceedings 22:564, 2003. | |
| 123. | Liu Q, Fayad LE, Hagemeister FB, Rodriguez MA, Younes A, Pro B, Vertovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P. Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. Blood 102:398a (#1446), 2003. | |
| 124. | Younes A, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang N, Samaniego F, Rodriguez MA, Fayad LE. Taxol Plus Topotecan Plus Rituximab (TTR) with G-CSF Support: An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma (NHL) Who Failed Failed CHOP-Like and Platinum-Based Therapy. Blood 102:142a (#489), 2003. | |
| 125. | Romaguera JE, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros LJ, Pro B, Younes A, Sarris AH, Dang NH, Samaniego F, Brown HM, Ganeja HK. . Blood 100:281b, 2002. | |
| 126. | Younes A, Robertson MJ, Flinn IW, Romaguera J, Hagemeister FB, Cabanillas F, Rodriguez MA, Dang N, Samaniego F. A phase II study of Interleukin-12 (IL-12) in patients with relapsed non-Hodgkin’s lymphoma and Hodgkin’s disease. Blood 100:364a, 2002. | |
| 127. | Rodriguez MA, Sarris A, East K, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera J, Samaniego F, Younes A, Cabanilla F. A Phase II study of liposomal vincristine in CHOP with Rituximab for patients with untreated aggressive B-cell non-Hodgkin’s lymphoma (NHL): A safe and effective combination. Blood 100:92a, 2002. | |
| 128. | Younes A, McLaughlin P, Pro B, Hagemeister FB, Fayad L, Romaguera J. Activity of Oxaliplatin in patients with relapsed and refractory non-Hodgkin’s lymphoma. Blood 110:296b, 2002. | |
| 129. | Khouri IF, Saliba RM, Hosing C, Okoroi GJ, Donato ML, Younes A, Acholonu S, McLaughlin P, Andersson B, Rodriguez MA, Korbling M, Cabanillas F, Champlin R. Concurrent administration of high-dose Rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed B-Cell lymphomas: increased efficacy without added toxicity. Blood 100:645a (#2538), 2002. | |
| 130. | Tsimberidou AM, McLaughlin P, Feng L, Ayala A, Younes A, Rodriguez MA, Romaguera J, Hagemeister FB, Smith TL, Cabanillas F. Duration of decreased absolute number of circulating CD4 cells and CD4/8 ratio in patients with indolent lymphoma treated with Fludarabine. Blood 100:775a (#3064), 2002. | |
| 131. | Younes A, Pro B, Hagemeister FB, Rodriguez MA, McLaughlin P, Fayad L, Goy A, Cabanillas F. Efficacy of single administration of a fixed dose Pegfilgtrastim (Neulasta) in inducing neutrophil count recovery after Paclitaxel plus Topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin’s lymphoma. Blood 100:727a, 2002. | |
| 132. | Czuczman MS, Witzig TE, Younes A, Moore JO, Vose JM, Miller TP, Grint PC, Leigh BR. IDEC-14 an anti-CD80 monoclonal antibody for relapsed or refractory follicular NHL: phase I/II study of safety, efficacy, and pharmacokinetics. Blood 100:1631, 2002. | |
| 133. | Younes A, Hagemeister F, Romaguera J, Samaniego F, McLaughlin P, Rodriguez MA, Medeiros LJ, LaMotte C, Ha C, Wilder R, Cabanillas F. Interferon alpha plus ABVD for the treatment of patients with classical Hodgkin’s disease. Blood 100:308b, 2002. | |
| 134. | Zhang B, Fiumara P, Li Y, Snell B, Younes M, Ashkenazi A, Carbone A, Younes A,. MEK1/2 is constitutively active in primary and cultured Hodgkin’s disease cells: A potential therapeutic target. Blood 100(352a), 2002. | |
| 135. | Zelenetz AD, Saleh M, Vose J, Younes A, Kaminiski MK. Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmuno-therapy with Tositumomab and iodine I-31 Tositumomab (Bexxarâ). Blood 100:357a, 2002. | |
| 136. | Bartlett NL, Younes A, Carabasi MA, Espina, DiPersio JF, Schlieber SD, Siegall C, Sing AP. Phase I study of SGN-30, a chimeric monoclonal antobidy (mAB), in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 100:362a, 2002. | |
| 137. | Goy A, Sarris AH, Bleyer A, Duvic M, Mesina O, Dang NH, Fayad L, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Romaguera J, Samaniego F, Younes A, Cabanillas F. Phase Ii study of compound GW506U78 (AraG) in patients with T-cell and B-cell non-Hodgkin’s lymphomas (NHL). Blood 110:304b, 2002. | |
| 138. | Dang NH, Hagemeister FB, Fayad L, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Younes A, Goy A, Preti A, Jones D, Sarris A, East K, Rodriguez MA, Cabanillas F. Phase II study of Delineukin Difitox (ONTAKâ) for relapsed/refractory B and T cell non-Hodgkin’s lymphoma. Blood 100:363a, 2002. | |
| 139. | Pro B, Romaguera J, Macapinlac HA, Fayad L, Dang NH, Samaniego F, Goy A, Rodriguez MA, McLaughlin P, Podoloff DA, Hagemeister F, Younes A, Cabanillas F. Positron emission tomography using fluorodeoxyglycose but not gallium-67 scintigraphy is a sensitive imaging modality in the staging of mantle cell lymphoma. Blood 100:769a, 2002. | |
| 140. | Leonard JP, Vose J, Younes A. Remission inversion in patients with low grade and transformed low grade NHL: Duration of response following treatment with Tositumomab and Iodine I-131 Tositumomab (Bexxar â) reproducbiity exceeds that produced by the preceding therapy. Blood 110:314b, 2002. | |
| 141. | Younes A, Fayad L, McLaughlin P, Goy A, Romaguera JE, Rodriguez MA, Hagemeister FB, Samaniego F, Pro B, Medeiros JL, Ha C, Wilder R, Seifert A. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin’s disease. Blood 110:308b, 2002. | |
| 142. | Horning SJ, Younes A, Lucas J, Podoloff D, Jain V. Rituximab treatment failures: Tositumomab and iodine I-131 responses. Blood 100:357a (#1385), 2002. | |
| 143. | Younes A, Fayad L, Pro B, Romaguera J, Ha CS, Wilder R,. Safety and efficacy of prophylactic Pegfilgrastim in patients with Hodgkin’s disease receiving ABVD chemotherapy. Blood 100:171b, 2002. | |
| 144. | Pro B, Hagemeister FB, Rodriguez MA, Hess M, Romaguera J, McLaughlin P, Younes A, Sarris AH, Ha C, Cox J, Cabanillas F. . Proceedings of the American Society of Clinical Oncology 20:297a, 2001. | |
| 145. | Khouri IF, Saliba RM, Younes A, Acholonu S, Andersson B, Bibawi S, de Lima M, Fayad L, Giralt S, Hagemeister FB, Korbling M, Rodriguez MA, Romaguera J, Cabanillas F, Champlin RE. Allogeneic transplantation for poor risk mantle cell lymphoma (MCHL): Chemosensitivity predicts superior outcome. Blood98 11(416a), 2001. | |
| 146. | Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning J, Medeiros LJ, Martinez RF, Cabanillas F. Depletion of normal B-lymphocytes by Rituximab therapy alters serum cytokine levels, resolves B- symptoms and induces clinical remissions in patients with relapsed classical Hodgikin’s disease (HD). Blood 98(11):132a, 2001. | |
| 147. | Fiumara P, Snell V, Li Y, Muhkopadhyay A, Younes M, Andreeff M, Cabanillas F, Carbone A, Aggarwal B, Younes A. Differential activity of TRAIL/Ajpo-2L in Hodgkin’s. Blood 98(11):599a, 2001. | |
| 148. | Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB, Younes A. Functional expression of RANK in Hodgkin’s disease (HD) cell lines: Regulation of chemokine and cytokine expression. Blood 98(11):598a, 2001. | |
| 149. | Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. High response rate and complete remission rate achieved by adding Rituximab to Taxol plus Topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma. Blood 98(11):345a, 2001. | |
| 150. | Cabanillas F, Ha CS, Lee MS, McLaughlin P, Rodriguez MA, Younes A, Sarris AH, Romaguera J, Pro B, Samaniego F, Cox JD. Intensive central lymphatic irradiationcan induce systemic molecular responses as measured by bcl-2 PCR assay: Results of a randomized study of radiation vs intensive chemotherapy for early stage I-III indolent follicular non-Hodgkin’s lymphomas (NHL). Blood 98(11):239b, 2001. | |
| 151. | Fiumara P, Cabanillas F, Younes A. Interleukin 13 (IL-13) levels in serum from patients with Hodgkin disease (HD) and healthy volunteers. Blood 98(11):129a, 2001. | |
| 152. | Younes A, Hagemeister F, Romaguera J, Dang N, Fiumara P, McLaughlin P, Rodriguez MA, Samaniego F, Khouri I, Cabanillas F. Interleukin-12 (IL-12) decreases serum VEGF and b-FCG levels and induces clinical remissions in patients with relapsed non-Hodgkin’s lymphoma (NHL). Blood 98(11):612a, 2001. | |
| 153. | Khouri IF, Saliba RM, Giralt S, Okoroji GJ, Younes A, Fayad L, Korbling M, Rodriguez MA, Couriel D, Bibawi S, Hosing C, McMannis J, Cabanillas F, Champlin RE. Long term remsision and low mortality achieved with Cispatin, Fludarabine, Cytarabine nonablative preparative regimen and allogeneic stem transplantation (AST) for h istologically aggressive Non-Hodgkin’s lymphoma (NHL). Blood 98(11):190a, 2001. | |
| 154. | Romaguera J, Cabanillas F, Dang NH, Goy A, Hagemeister FB, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros J. Mantle cell lymphoma (MCL) – High rates of complete remission (CR) and prolonged failure- free survival (FFS) with rituxan-hyperCVAD ( R-HCVAD) without stem cell transplant (SCT). . Blood 98(11):726a, 2001. | |
| 155. | Rodriguez MA, Dang NH, East K, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Samaniego F, Sarris A, Younes A, Cabanillas F. Melatonin did not prevent CHOP-induced myelosuppression in patients with aggressive lymphoma: Results of a randomized study. Blood 98(11):247b, 2001. | |
| 156. | Khouri IF, Saliba RM, Lee MS, Giralt S, Younes A, Couriel D, Fayad L, de Lima M, Hagemeister FB, Hosing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewski J, Cabanillas, Champlin RE. Nonablative allogeneic stem cell transplantation (AST) for non-Hodgkin’s lymphoma (NHL): Improved outcome with low incidence of acute GVHD and treatment related mortality. Blood 98(11):416a, 2001. | |
| 157. | Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Rodriguez MA, Sarris AH, Jones D, East K, Gomez R, Fayad LE, Pro B, McLaughlin P, Samaniego F, Goy A, Cabanillas F. Phase II study of Pentostatin for relapsed T cell lymphomas: Efficacy and effect on CD26+ T cells. Blood 98(11):130a, 2001. | |
| 158. | Pro B, Younes A, Albitar M, Hagemeister FB, Rodriguez MA, McLaughlin P, Clemons M, Samaniego F, Cabanillas F. Phase II study of thalidomide in patients with recurrent Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL). Blood 98(11):246b, 2001. | |
| 159. | Konopleva MK, McQueen T, Tsao T, Monaco G, Lapillone H, Wang RY, Younes A, Belmont J, Sporn MB, Andreeff M. PPARg ligands are potent inducers of apoptosis in leukemias and lymphoma. Blood 98(11):119a, 2001. | |
| 160. | Fayad LE, Romaguera J, Pro B, Younes A, Dang NH, Samaniego F, GarciaTejido P,Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, Cabanillas F, Rodriguez P. Primary mediastinal large B-cell lymphoma (PMLBL): Poor prognosis in patients with extranodal sites. Blood 98(11):336a, 2001. | |
| 161. | Khouri I, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas F, Champlin RE. Prolonged failure-free survival and molecular reponses with nonablative alloeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma. Blood 98(11):744a, 2001. | |
| 162. | Barista I, Hagemeister FB, Podoloff DA, Rodriguez MA, McLaughlin P, Romaguera JE, Ha CS, Wilder RB, Younes A, Sarris A, Cabanillas F. The positive (POS) gallium scan ( GA-67) in Hodgkin’s disease (HD) at end of therapy predicts freedom from progression (FFP) and overall survival (OS) results. Blood 98(11):126a, 2001. | |
| 163. | Khouri IF, Giralt S, Saliba R, Korbling M, Gajewski J, Younes A, Romaguera J, Anderlini P, Rodriguez MA, Donato ML, Ippoliti C, Keating M. “Mini”-allogeneic stem cell transplantation for relapsed/refractory lymphomas with aggressive histologies. Proceedings of American Society of Clinical Oncology 19:47a, 2000. | |
| 164. | Khouri I, Saliba R, Giralt S, Hagemeister F, Korbling M, Younes A, Gajewski J, Ueno N, Anderlini P, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation for indolent lymphomas: Improved outcome with non-myeloablative versis high dose chemotherapy (HDCT) regimens. Blood 96(11):199a, 2000. | |
| 165. | Rodriguez MA, Cabanillas F, Dang NH, Grimm EA, McLaughlin P, McAda N, Hagemeister FB, Romaguera J, Sarris A, Younes A, Richardson MA. Lymphocyte changes in lymphoma patients receiving melatonin plus CHOP-chemotherapy. Proceedings of American Society of Clinical Oncology 19:20a, 2000. | |
| 166. | Gordon L, Moore J, Cheson B, Czuczman M, Younes A, Leonard J, Forero A, Sweetenham J, Chieffo N, Thall A, Leigh B. Phase I Results from a multicenter Trial Of Galiximab (Anti-CD80 Antibody, IDEC-114) in Combination with Rituximab for the Treatment of Follicular Lymphoma. Blood 102:307b (#4951), 2000. | |
| 167. | Romaguera JE, Dang NH, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Medeiros J, Steinbach G, Cabanillas F. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL). . Blood 96(11):733a, 2000. | |
| 168. | Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris, A, Romaguera J, Preti A, Lee MS, Cabanillas F. Randomized comparison of fludarabine-novantrone-dexamethasone (FND) versus CHOD-Bleo/ESHAP/NOPP (Alternating triple therapy; ATT) in patients with stage IV indolent lymphoma. Blood 96(11):508a, 2000. | |
| 169. | Snell V, Li Y, Mukhopadhyay A, Younes M, Andreeff M, Cabanillas F, Carbone A, Aggarwal BB, Younes A. Resistance of Hodgkin’s disease cell lines to TRAIL is independent of its receptor expression, cFLIP, and NF-kB. Blood 96(11):727a, 2000. | |
| 170. | Younes A, Fayad LE, Pro B, McLaughlin P, Hagemeister FB, Mansfield P, Clayman G, Medeiros JL, Manning J, Lewis j, Strivastava P. Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine Therapy in Patients with Relapsed or Previously Untreated Low-Grade Non-Hodgkin Lymphoma. Blood 102:898a-899a (#3343), 2000. | |
| 171. | Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff, Younes A. Functional Expression of TRAIL by Lymphoid and Myeloid Tumor Cells. Annals of Oncology. Proc Intl Conf Malig Lymphoma, Lugano, Switzerland 10(3), 6/1999. | |
| 172. | Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera J, Younes A, Sarris A, Preti HA, Pugh W, Lee MS. Molecular Response Assessed by PCR is the Most Important Factor Predicting Failure-Free Survival (FFS) in Indolent Follicular Lymphoma (FL). Update of the MDACC Series. Annals of Oncology. Proc Intl Conf Malig Lymphoma, Lugano,Switzerland 10(3), 6/1999. | |
| 173. | Clodi K, Asgary Z, Zhao S, Younes M, Wimmer Doris, Cabanillas F, Andreeff M, Younes A. CD40L is Overexpressed on B Cells of Hodgkin’s Disease (HD): Rationale for a Pilot Trial Using Anti-CD20 Antibody. Annals of Oncology 10(3), 1999. | |
| 174. | Fayed L, Rodriguez MA, Romaguera J, Hagemeister F, Younes A, Sarris A, Romaguera J, McLaughlin P, Cabanillas F. Gallium (67Ga) Scan Result After Second or More Cycles of Chemotherapy Correlates With Clinical Outcome in Aggressive Good Prognosis NHL (AGPNHL). . Proc ASCO 18:17a, 1999. | |
| 175. | Rodriguez J, Cabanillas F, McLaughlin P, Rodriguez M, Hagemeister FB, Romaguera J, Sarris AH, Younes A. Serum B-2 Microglobulin Improves the Prognostic Discrimination of the International Prognostic Index (IPI). . Annals of Oncology 10(3), 1999. | |
| 176. | Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin PW, Sarris AH, Younes A, Rodriguez J, Pate O, Keating MJ, Koller CA, Riggs SA, Champlin R, Cabanillas F. Untreated Aggressive Mantle Cell Lymphoma (MCL) Presents With Frequent Gastrointestinal Involvement and Has High Complete Response (CR) Rates With Intensive dChamotherapy (IC) Without Stem Cell Transplant. Annals of Oncology 10(3), 1999. | |
| 177. | Anderlini P, Andersson B, Gajewski J, Giralt S, Mehra R, Sarris A, Claxton D, Ueno N, McLaughlin P, Khouri I, Hagemeister F, Przepiorka D, Younes A, Donato M, Romaguera J, Rodriguez M, Korbling M, Cabanillas F, Champlin R. Allogeneic Stem Cell Transplantation for Advanced Hodgkin’s Disease: The M.D. Anderson Experience. Proc ASCO 17:88a, 1998. | |
| 178. | Cabanillas F, Lee MS, McLaughlin P, Cox J, Hagemeister FB, Ha C, Rodriguez MA, Romaguera J, Sarris A, Younes A. Detection of Minimal Residual Disease By bcl-2 PCR in Early Stage Follicular Lymphomas (FL). . Blood 92(10 Suppl 1):316a, 1998. | |
| 179. | Wang Y, Asgary Z, Cabanillas F, Younes A. In Vivo Regulation of Fas Ligand (FasL) Expression in Peripheral Blood Lymphocytes (PBL) of Patients With Relapsed Hodgkin’s Disease (HD): Results of a Pilot Clinical Trial of Interferon-a and GM-CSF (Ifn + GM) Cytokine Therapy. Blood 92(10 Suppl 1):4056a, 1998. | |
| 180. | Younes A, Rahman R, Hagemeister F, Romaguera J, McLaughlin P, Cabanillas F. Phase II Study of Paclitaxel Plus Topotecan With G-CSF Support For the Treatment of Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma. Blood 92(10 Suppl 1):621a (#256), 1998. | |
| 181. | Younes A, Messina O, McLaughlin P, Hagemeister F, Weber D, Bachier C, Cabanillas F. Phase II Trial of Oral Panretin (9-Cis Retinoic Acid) in Patients With Relapsed Non-Hodgkin’s Lymphoma (NHL). . Proc ASCO 17:41a, 1998. | |
| 182. | Andreeff M, Champlin R, Younes A. Potential Involvement of Fas Ligand (FasL) in the Pathogenesis of Human Graft-vs-Host Disease (GVHD). . Blood 92(10 Suppl 1):639a, 1998. | |
| 183. | Rodriguez MA, Swan F, Hagemeister F, Hess M, McLaughlin P, Romaguera J, Sarris A, Younes A, Cabanillas F. Tumor Score System (TSS) Selects a Highly Favorable Subset of Patients (PTS) With Large Cell Lymphoma. Proc ASCO 17:35a, 1998. | |
Book Chapters | ||
| 1. | Georgakis G Younes A. Cytokines in Lymphoma., 2005. | |
| 2. | Younes A Cerutti P. TNF Family in Cancer Therapy. Humana Press, 2004. | |
| 3. | Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis. Molecules and mechanisms. In: Adv Exp Med Biol. 457, 217-236, 1999. | |
| 4. | Escudier S Younes A. Fluerescence in situ hybridization studies of lymphoproliferative malignancies. In: FISH: Clinical Applications in Cancer and Genetics, 1999. | |
| 5. | Kemeny N Younes A. Chemotherapeutic Liver Infusion. In: Colorectal Cancer. Mosby-Yearbook, 1993. | |
Letters to the Editor | ||
| 1. | Bertrand Coiffier, Arnold Altman, Ching-Hon Pui, Anas Younes, and Mitchell S. Cairo. In Reply. J Clin Oncol 26:5658-5659, 12/2008. | |
| 2. | Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 92(2):269-70, 2/2007. PMID: 17296586. | |
| 3. | Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/2007. PMID: 17133412. | |
| 4. | Anas Younes, Barbara Pro, and Luis Fayad. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107(4):1731a-1732, 2/15/2006. PMID: 16461762. | |
| 5. | Mukhopadhyay A, Fiumara A, Li Y, Darnay BG, Aggarwal B, Younes A. Receptor Activator of Nuclear Factor-kB (RANK) Ligand Activates Mitogen-Activated Protein Kinases Signaling Pathways in Hodgkin/Reed-Sternberg Cells. Blood, 2002. | |
| 6. | Younes A. CD40 ligand therapy of lymphoma patients. J Clin Oncol 19:4351-4352, 2001. | |
| 7. | Fiumara P, Cabanillas F, Younes A. IL-13 in sera of patients with Hodgkin disease. Blood 98:2877-2878, 2001. | |
| 8. | Younes A. Paclitaxel for the treatment of lymphoma. J Clin Oncol 16(6):2289-2290, 1998. | |
| 9. | Younes A. Are activated cytotoxic T cells in Hodgkin’s disease biopsies a poor prognostic marker? . Blood 90:890, 1997. | |
| 10. | Ayoub JP, North L, Greer J, Cabanillas F, Younes A. Pulmonary changes in patients with lymphoma who receive paclitaxel. J Clin Oncol 15(6):2476, 1997. | |
| 11. | Younes A. Cytogenetic findings in T-cell lymphoma of angioimmunoblastic lymphadenopathy. J Clin Oncol 14(7):2188, 7/1996. | |
| 12. | Younes A. Numerical Chromosome aberrations in CD30-positive cells of Hodgkin's diseases: Truth or Fiction? . Blood, ltr. 87(10):4479-4481, 5/1996. | |
Manuals, Teaching Aids, Other Teaching Publications | ||
| 1. | The Lymphoma Section Teaching Manual for Fellows: A yearly updated collection of state of the art articles related to clinical and biological aspects of lymphoma., 1992. | |
Last updated: 9/14/2009
- Global Navigation
- About Us
- Locations
- Events
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient & Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children’s Cancer Hospital
- Services & Amenities
- Physician Directory
- Education and Research
- Departments, Programs & Labs
- PeopleFinder
- Research at M.D Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alerts
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
© 2009 The University of Texas M. D. Anderson Cancer Center